Navigation Links
Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
Date:1/28/2009

HONOLULU, Jan. 28 /PRNewswire/ -- Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

In the study, leconotide, when given intravenously to treat neuropathic pain, was selective for calcium channels involved with pain and it did not act on other calcium channels to cause side effects, as has been seen in studies of other calcium channel blockers used for treating pain. It was efficacious alone, but more so when it was given in combination with a potassium channel opener (flupirtine). The study also showed that leconotide, unlike currently available treatments of this type, does not have to be administered directly into the spinal fluid to achieve pain relief, and so could have the potential to be delivered via nasal spray, transdermal patch, or pill.

Leconotide was also compared with ziconotide, an established calcium channel blocker, which was given intravenously with and without flupirtine. In this study, ziconotide was not an effective pain reliever, given alone or in combination with flupirtine.

"There is a tremendous need for non-opioid treatments for neuropathic pain, so the results of this study are exciting for researchers in the field of pain medicine, doctors whom treat pain, and patients who suffer or are under-treated because of the abuse potential and side effects associated with opioid treatments," said Colin Goodchild, PhD, and director of the Centre for Pain Research and Palliative Care, Monash Institute of Medical Research.

To determine the efficacy and side effect profile of leconotide, researchers at Monash Instit
'/>"/>

SOURCE American Academy of Pain Medicine
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
2. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
3. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
4. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
5. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
6. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
7. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
8. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
9. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
10. VA-NIH Study Offers Hope for Parkinsons Patients
11. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...IN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- ...l" or "the Company") (Nasdaq: CSKI ), a,leading f...and producing,over-the-counter drugs in the People... the Company recently passed the Chinese National ...ological Products ("ICPBP") examination,for two of...
(Date:11/25/2009)..., Mass., Nov. 25 According to Mill...on medical technology market intelligence, the nea...es will continue to see rapid growth over the next...MRG,s US Markets for Trauma Devices 2010 repor...c over the next five years, with competitors intro...
(Date:11/25/2009)... The Netherlands and JOHANNESBURG, November 25 /PR...sion and Pyxis Discovery announced today,that they...market both,companies, services. , Pyxis,...covery expertise,will be coupled with iThemba,s se...chemistry support to projects identified through P...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Pancreatic cancer risk decreased by one anti diabetic therapy increased by others 53409 1Pancreatic cancer risk decreased by one anti diabetic therapy increased by others 53409 2Dementia induced and blocked in Parkinsons fly model 53406 1Dementia induced and blocked in Parkinsons fly model 53406 2Dementia induced and blocked in Parkinsons fly model 53406 3House Tri Committee Bill Would Hurt Patients and Kill Jobs 53405 1House Tri Committee Bill Would Hurt Patients and Kill Jobs 53405 2House Tri Committee Bill Would Hurt Patients and Kill Jobs 53405 3
...UPERTINO, Calif., Aug. 12 DURECT Corporation,(Nas...Drug Administration,(FDA) has accepted the New Dru...ity Review. The FDA typically grants Priority Revi...emonstrate significant improvements,compared to ma...w of a drug,with Priority Review status is six mon...
...wing to Well-Established and Effective Insulin-Bas... 2017, According to a New Report from Decision ...ss., Aug. 12 Decision Resources, one of the,world...eutical and,healthcare issues, finds that the most...es market will be the shift in the standard of car...
Other Medicine Technology:REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 2REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 3Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market 2
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)..., NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewswir...rofessional cycling team dedicated to ethical spor... champions, announced today that it will become Te...ions Optical as a new sponsor of the team. Transit...f adaptive eyewear, offering the most advanced pho...
(Date:11/27/2009)... XenaCare Holdings has announced t...tis Foundation, one of the largest nonprofit organ...c health education. , Del...e Holdings, Inc. (OTCBB: XCHO), a company speciali...onsumer healthcare products, has announced today t...
(Date:11/27/2009)...ates to bring unprecedented medical, economic burd...(HealthDay News) -- The number of people with diab...er the next 25 years, a new study predicts. , T...llion people with the disease, up from 23.7 millio...ing people with diabetes will triple, the study al...
(Date:11/27/2009)... Voyant Health™ announced to...has licensed its TraumaCad Enterprise orthopedic t...ow solution. , (PRWEB) No...today that Spectrum Health (Grand Rapids, Michigan... templating solution and its TraumaCad Extend work...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...ey, California have come out with a tremendous tec... information held in store in the human genome. Th...dowing". An analysis through this technique helps ... patterns' that identify these primate families un...
...t cancer are put off just with the news and then f...akes 6 weeks, disrupts their world completely. How...asier and less disruptive way of treating these ca...doctors will now be able to deliver the same cance...
...attempt to find out how various eating styles were...mpared the blood pressures of meat eaters, fish ea...ch were published in Public Health Nutrition, show...blood pressure and others with normal blood pressu...
...are one of the most exquisite pieces of engineerin...the eyes become vulnerable to a debilitating degen...eaking down, which ultimately might lead to blindn...ough nutrients that work as antioxidants. The...
... sharp rise in the use of alternative treatments a...entifically document the effects of hundreds of he...now, there was// no easy access to current, compre...ill provide up-to-date information on the safety a...
...y of us, though very annoying, are just a harmless...for many sick people who have weakened immune syst...ttacks launched against their blood vessels and in...ering them ineffective for treatment of several se...
Other Medicine News:Health News:Primates reveal a new dimension to human genome, 2Health News:Cut meat to cut blood pressure 2Health News:New insights into herbal supplements 2Health News:Fight against Fungus - A new ray of hope 2
RESTASIS®
LADARWave® Aberrometer
ZYMAR™ 2.5 mL
REFRESH TEARS®
Medicine Products: